Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study

被引：0

作者：

le Coutre, Philipp D. ^{[1
]}

Giles, Francis J. ^{[2
,3
]}

Pinilla-Ibarz, Javier ^{[4
]}

Larson, Richard A. ^{[5
]}

Gattermann, Norbert ^{[6
]}

Ottmann, Oliver G. ^{[7
]}

Hochhaus, Andreas ^{[8
]}

Radich, Jerald P. ^{[9
]}

Saglio, Giuseppe ^{[10
]}

Hughes, Timothy P. ^{[11
]}

Martinelli, Giovanni ^{[12
]}

Kim, Dong-Wook ^{[13
]}

Branford, Susan ^{[11
]}

Mueller, Martin C. ^{[14
]}

Shou, Yaping ^{[15
]}

Novick, Steven ^{[16
]}

Fan, Xiaolin ^{[16
]}

Cortes, Jorge E. ^{[17
]}

Baccarani, Michele ^{[12
]}

Kantarjian, Hagop M. ^{[17
]}

机构：

[1] Charite, D-13353 Berlin, Germany

[2] Natl Univ Ireland Galway, Galway, Ireland

[3] Trinity Coll Dublin, Galway, Ireland

[4] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Univ Dusseldorf, D-40225 Dusseldorf, Germany

[7] Univ Klin Frankfurt, Med Klin 2, MRD Lab, Frankfurt, Germany

[8] Univ Klinikum Jena, Jena, Germany

[9] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[10] Univ Turin, Orbassano, Italy

[11] Royal Adelaide Hosp, SA Pathol, Adelaide, SA 5000, Australia

[12] Univ Bologna, Bologna, Italy

[13] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[14] Univ Heidelberg, Med Klin 3, Med Fak Mannheim, D-6800 Mannheim, Germany

[15] Novartis Inst BioMed Res, Cambridge, MA USA

[16] Novartis Pharmaceut, E Hanover, NJ USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1610 / 1610

页数：1

共 50 条

[31] Nilotinib versus imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 3-year (yr) follow-up (f/u)
Kantarjian, Hagop
Flinn, Ian W.
Goldberg, Stuart
Bunworasate, Udomsak
Zanichelli, Maria Aparecida
Nakamae, Hirohisa
Hughes, Timothy P.
Hochhaus, Andreas
Saglio, Giuseppe
Woodman, Richard Charles
Blakesley, Rick E.
Kemp, Charisse N.
Kalaycio, Matt E.
Larson, Richard A.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] Long term follow-up of frontline dasatinib in patients (pts) with early chronic phase chronic myeloid leukemia (CML-CP).
Maiti, Abhishek
Kantarjian, Hagop M.
Patel, Keyur
Borthakur, Gautam
Ravandi, Farhad
Verstovsek, Srdan
Ferrajoli, Alessandra
Estrov, Zeev
Kadia, Tapan M.
Skinner, Jeffrey A.
Poku, Rebecca A.
Dellasala, Sara
Luthra, Rajyalakshmi
Jabbour, Elias
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[33] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
Giles, Francis J.
le Coutre, Phillip
Bhalla, Kapil N.
Ossenkoppele, Gert
Alimena, Giuliana
Haque, Ariful
Gallagher, Neil
Kantarjian, Hagop M.
BLOOD, 2007, 110 (11) : 311A - 312A
[34] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
Hoyle, Martin
Rogers, Gabriel
Moxham, Tiffany
Liu, Zulian
Stein, Ken
VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
[35] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
Ottmann, O. G.
le Coutre, P.
Gattermann, N.
Hochhaus, A.
Bruemmendorf, T. H.
Kindler, T.
Duyster, J.
Al-Ali, H.
Lipton, J.
Wang, J.
Yang, M.
Szczudlo, T.
Giles, F.
ONKOLOGIE, 2010, 33 : 138 - 138
[36] Watching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial
Cortes, Jorge E.
De Souza, Carmino Antonio
Lopez, Jose Luis
Ayala, Manuel
Bullorsky, Eduardo
Huang, Xiaojun
Shah, Sandip
Babu, K. Govind
Sacha, Tomasz
Bendit, Israel
Liang, Zhizhou
Owugah, Tina
Nidamarthy, Prasanna Kumar
Szczudlo, Tomasz
Piccolo, Carmen
le Coutre, Philipp D.
BLOOD, 2013, 122 (21)
[37] Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.
Larson, Richard A.
Hochhaus, Andreas
Saglio, Giuseppe
Rosti, Gianantonio
Lopez, Jose L.
Stenke, Leif
Nakamae, Hirohisa
Goldberg, Stuart L.
Wang, Ming-Chung
Gallagher, Neil J.
Hoenekopp, Albert
Ortmann, Christine-Elke
Hughes, Timothy P.
Kantarjian, Hagop M.
BLOOD, 2010, 116 (21) : 944 - 945
[38] Nilotinib Exposure-Response Analysis In Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML)
Giles, Francis J.
Yin, Ophelia
Chia, Yen Lin
le Coutre, Philipp D.
Woodman, Richard C.
Ottmann, Oliver G.
Baccarani, Michele
Kantarjian, Hagop M.
BLOOD, 2010, 116 (21) : 390 - 390
[39] Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up
Lipton, Jeffrey Howard
Hughes, Timothy P.
Leber, Brian
De Souza, Carmino
Dorlhiac-Llacer, Pedro E.
Steegmann, Juan Luis
Guerci-Bresler, Agnes
Schwarer, Anthony P.
Cervantes, Francisco
Reynolds, John
Collins, LaTonya R.
Szczudlo, Tomasz K.
Spector, Nelson
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[40] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
Koren-Michowitz, M. K. M.
Le Coutre, P.
Duyster, J.
Scheid, C.
Rowe, J. M.
Goldschmidt, N.
Ribakovsky, E.
Nagler, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223

← 1 2 3 4 5 →